Galapagos NV announced the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO),effective April 1, 2022.Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development,and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas. Previously, Paul was Vice Chairman of the Executive Committee and Chief Scientific Officer of J&J, where he spearheaded the Company's research and product pipeline to set the company wide innovation agenda, discovering and developing transformational healthcare solutions, including the recent development of a single-shot COVID-19 vaccine within a record time frame. After a transition period during which Onno will hand over his activities, Paul Stoffels will fully take over as CEO effective April 1, 2022.